The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

What Was Tested

In this not phased trial, researchers set out to test Oxytocin and Vasopressin.

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

It had three arms (groups): oxytocin (experimental), vasopressin (experimental) and placebo (placebo comparator).

The registry classes the interventions as drug.

More on the Plan

A double-blinded, placebo-controlled, between-subject design is employed in this study.

In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo.

(1) 15-minute resting-state EEG data are collected 35 minutes after treatment.

(2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected.

Who Took Part

The registry lists 120 actual participants took part.

It was open to people of any sex aged from 18 years up to 30 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Healthy subjects without past or current psychiatric or neurological disorders.

The full record lists 1 inclusion and 3 exclusion criteria; among the exclusions: history of head injury; pregnant,menstruating,taking oral contraceptives; medical or psychiatric illness.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Oxytocin group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2024-10-02 with completion listed for 2025-07-28.

It ran at 2 sites in China (2).

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Resting-state EEG (time frame: 35-50 minutes after treatment administration). Behavioral indices in the tasks (time frame: 50-90 minutes after treatment administration). Task-based EEG (time frame: 50-90 minutes after treatment administration).

It also tracked 1 secondary outcome, for example SCR in anxiety induction.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Oxytocin and Vasopressin in 120 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page and the Vasopressin compound page, all human trials.